Dudediligence.

Fate Therapeutics, Inc

FATENASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$3.1MSep ’24$1.9MDec ’24$1.6MMar ’25$1.9MJun ’25$1.7MSep ’25$1.4MDec ’25$1.3MMar ’26$2.1MJun ’26
Net income, by quarter
−$47.7MSep ’24−$52.2MDec ’24−$37.6MMar ’25−$34.1MJun ’25−$32.3MSep ’25−$32.4MDec ’25−$31.2MMar ’26−$30.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$55.8M$96.3M$63.5M$13.6M$6.6M
Operating income−$217.0M−$308.4M−$190.5M−$210.3M−$147.7M
Net income−$212.2M−$281.7M−$160.9M−$186.3M−$136.3M
Operating cash flow−$162.9M−$248.2M−$132.3M−$122.9M−$106.1M
Free cash flow−$213.6M−$283.8M−$138.4M−$123.6M−$112.0M
Cash$133.6M$61.3M$41.9M$36.1M$46.6M
Shares outstanding95.7M97.3M98.6M113.9M115.4M